

Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients With Metastatic Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor: Results of the Phase 3 TiNivo-2 Study

<u>Toni K. Choueiri,</u>¹ Robert J. Motzer,² Kathryn E. Beckermann,³ Philippe Barthélémy,⁴ Roberto Iacovelli,⁵ Sheik Emambux,⁶ Javier Molina-Cerrillo,⁷ Benjamin Garmezy,⁸ Pedro Barata,⁹ Rana R. McKay,¹⁰ Alexander Chehrazi-Raffle,¹¹ Hans Hammers,¹² Daniel Y.C. Heng,¹³ Edgar Braendle,¹⁴ Bradley A. McGregor,¹ Laurence Albiges¹⁵

¹Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, US; ²Memorial Sloan Kettering Cancer Center, New York, NY, US; ³Vanderbilt University Medical Center, Nashville, TN, US; ⁴Institut de Cancerologie Strasbourg Europe, Strasbourg, France; ⁵Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; ⁶Centre Hospitalier Universitaire de Poitiers, Poitiers, France; ⁷Hospital Universitario Ramon y Cajal, Madrid, Spain; ⁸Sarah Cannon Research Institute, Nashville, TN, US; ⁹University Hospitals Seidman Cancer Center, Cleveland, OH, US and Tulane University School of Medicine, New Orleans LA, US; ¹⁰University of California, San Diego, CA, US; ¹¹City of Hope, Los Angeles, CA, US; ¹²University of Texas Southwestern Medical Center, Dallas, TX, US; ¹³Tom Baker Cancer Center, Calgary, AB, Canada; ¹⁴AVEO Oncology, Boston, MA, US; ¹⁵Institut Gustave Roussy, Villejuif, France

*Dr. Albiges and Dr. Motzer were equal contributors

LBA73 September 13, 2024

Declaration of Interests

- Dr. Toni Choueiri reports institutional and/or personal, paid and/or unpaid support for research, advisory boards, consultancy, and/or honoraria in the past 5 years, ongoing or not, from:
 - Alkermes, Arcus Biosciences, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Deciphera Therapeutics, Eisai, EMD Serono, Exelixis, GSK, Gilead, HiberCell, IQVIA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Neomorph, Neucon/Precede Biosciences, Novartis, OncoHost, Pfizer, Roche, Sanofi-Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, UpToDate, CME events (Peerview, OncLive, MJH, CCO and others), outside the submitted work
 - Institutional patents filed on molecular alterations and immunotherapy response/toxicity, and ctDNA
 - Equity: Tempest, Pionyr, Osel, Precede Biosciences, Curesponse, InnDura Therapeutics, Premium
 - Committees: NCCN, GU Steering Committee, ASCO (BOD 6-2024), ESMO, ACCRU, KidneyCAN
 - Medical writing and editorial assistance support may have been funded by communications companies in part.
 - Mentored several non-US citizens on research projects with potential funding (in part) from non-US sources/foreign components
 - The institution (Dana-Farber Cancer Institute) may have received additional independent funding from drug companies or/and royalties potentially involved in research around the subject matter
 - T. K. Choueiri is supported in part by the Dana-Farber/Harvard Cancer Center Kidney SPORE (2P50CA101942-16) and Program 5P30CA006516-56, the Kohlberg Chair at Harvard Medical School, the Trust Family Foundation, Michael Brigham, Pan-Mass Challenge, Hinda L and Arthur Marcus Fund and Loker Pinard Funds for Kidney Cancer Research at Dana-Farber Cancer Institute
- This study was sponsored by AVEO Pharmaceuticals, Inc.



Background

- Immune checkpoint inhibitors (ICIs) are the cornerstone of the first-line treatment of advanced mRCC¹⁻⁴
- The optimal sequence in patients whose disease has progressed after treatment with ICIs is uncertain, leaving several unanswered questions:
 - Can ICI rechallenge improve clinical outcomes?
 - Can outcomes be impacted if non-ICIs were used before ICI rechallenge (ICI break)?
 - Are there any differences between anti–PD-1 or anti–PD-L1 therapies in the rechallenge setting?
- Evidence supports the value of VEGFR TKI use, including tivozanib, in patients previously treated with ICI-based regimens^{5,6}
- Tivozanib was evaluated in combination with nivolumab in the phase 1/2 TiNivo study, showing promising antitumor efficacy with an expected adverse event profile in patients with mRCC⁷
- To further explore retreatment with ICI, we conducted the phase 3 TiNivo-2 study of tivozanib in combination with nivolumab (anti–PD-1) compared with tivozanib in patients with mRCC following progression on prior ICI




mRCC, metastatic renal cell carcinoma; PD-1, programmed cell death 1 protein; PD-L1, programmed cell death 1 ligand 1; VEGFR-TKI, vascular endothelial growth factor receptor tyrosine kinase inhibitor.

1. Choueiri TK, et al. *N Engl J Med.* 2017;367(4):354-366. 2. Choueiri TK, et al. *J Natl Cancer Inst.* 2021;113(3):234-243. 3. Braun DA, et al. *Nat Rev Clin Oncol.* 2021;18(4):199-214. 4. Ravi P, et al. *Cancer J.* 2020;26(5):464-470. 5. Pal SK, et al. *Lancet.* 2023;402:185-195. 6. Rini BI, et al. *Lancet Oncol.* 2020;21:95-104. 7. Albiges L, et al. *Ann Oncol.* 2021;32:97-102.

TiNivo-2: Phase 3 Study Design

Locally advanced or metastatic clear cell RCC after progression on 1 or 2 lines of therapy, one of which was an ICI:

- Progression during or following ≥6 weeks of treatment with an ICI
- Time from immediate prior line of therapy to randomization ≤6 months
- Measurable disease (RECIST v1.1)
- ECOG PS: 0 or 1



Prior therapy (ICI as most recent therapy or not)

Reduced dose of tivozanib in combination arm was agreed with regulatory

Test if ICI break impacts outcome (to resensitize the immune system

authorities due to potential risk of higher rate of grade 3/4 hypertension

Stratification Factors

- IMDC risk category
- Prior therapy (ICI as most recent therapy or not)

Statistical Analysis

- 220 PFS events, statistically powered to detected an improvement of 4 months in PFS (HR=0.67)
- Stratified log-rank test with a two-sided 5% significance level

BARCELONA SOUTHING CONGRESS

 ^a Treatment was continued until progression or unacceptable toxicity; nivolumab was discontinued in all patients after 2 years of treatment.
D, day; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; ICI, immune checkpoint inhibitor; IMDC, International mRCC Database Consortium; INV, investigator; IRR, independent radiology review; IV, intravenous; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PO, by mouth; R, randomization; RCC, renal cell carcinoma; RECIST, Response Evaluation Criteria in Solid Tumors.
ClinicalTrials.gov. Accessed May 20, 2024. https://clinicaltrials.gov/study/NCT04987203

to ICI therapy)

Key Considerations

4

Baseline Demographics and Disease Characteristics


Characteristic	Tivozanib + Nivolumab (n=171)	Tivozanib (n=172)
Age, years Median (range)	64 (37-87)	63 (33-82)
Sex, n (%) Female Male	46 (27) 125 (73)	38 (22) 134 (78)
Race, n (%) White Asian Black or African American Not reported	112 (65) 1 (<1) 2 (1) 56 (33)	107 (62) 0 8 (5) 57 (33)
ECOG PS, n (%) 0 1 Missing	76 (44) 94 (55) 1 (<1)	85 (49) 87 (51) 0

Characteristic	Tivozanib + Nivolumab (n=171)	Tivozanib (n=172)
IMDC risk category, n (%) Favorable Intermediate Poor	30 (18) 114 (67) 27 (16)	31 (18) 113 (66) 28 (16)
Prior lines of therapy, n (%) 1 2	111 (65) 60 (35)	105 (61) 67 (39)
Most recent therapy, n (%) ICI Non-ICI	122 (71) 49 (29)	122 (71) 50 (29)
Prior VEGFR-TKI use, n (%) 0 1 2	53 (31) 96 (56) 22 (13)	53 (31) 101 (58) 18 (11)



ECOG PS, Eastern Cooperative Oncology Group performance status; ICI, immune checkpoint inhibitor; IMDC, International mRCC Database Consortium; VEGFR-TKI, vascular endothelial growth factor receptor tyrosine kinase inhibitor.


Primary Analysis of Centrally Reviewed PFS (primary endpoint)



Median follow-up was 11.8 months in the tivozanib + nivolumab cohort and 12.5 months in the tivozanib monotherapy arm



Centrally Reviewed PFS by Line of Therapy




Second-Line Therapy

Third-Line Therapy



Centrally Reviewed PFS by Most Recent Line of Therapy



ICI as Most Recent Therapy

Non-ICI as Most Recent Therapy




Centrally Reviewed PFS by Subgroups

	Tivoza	nib + Nivolumab		Tivozanib				
Category	Event/N	Median PFS (95% CI), months	Event/N	Median PFS (95% CI), months				PFS HR (95% Cl)
Age								
<65 years	68/89	4.8 (3.7-7.3)	65/97	7.4 (5.5-9.2)	┍╂╼■	—		1.25 (0.89-1.76)
≥65 years	50/82	9.2 (5.5-9.6)	47/75	7.6 (5.2-10.0)	⊢ ∎	ł		0.92 (0.61-1.37)
Sex								
Male	86/125	5.6 (3.9-7.5)	88/134	7.4 (5.5-9.2)		1		1.01 (0.75-1.36)
Female	32/46	6.7 (3.7-10.9)	24/38	7.4 (5.6-12.9)	┍╼╪╼∎			1.27 (0.75-2.16)
ECOG PS								
0	52/76	7.3 (4.0-9.4)	53/85	8.8 (7.2-11.1)	⊢∔∎−			1.15 (0.78-1.69)
1	66/94	5.5 (3.7-9.0)	59/87	6.0 (3.7-8.6)				0.95 (0.67-1.36)
IMDC risk category								
Favorable	18/30	9.3 (4.0-11.4)	15/31	11.2 (9.3-13.1)				1.37 (0.69-2.73)
Intermediate	78/114	5.7 (4.0-9.4)	75/115	7.4 (4.5-8.4)	⊢_			0.99 (0.72-1.36)
Poor	22/27	3.7 (2.7-7.4)	22/26	5.7 (2.3-9.2)			4	1.35 (0.73-2.50)
VEGFR-TKI use in most recent li	ne							
Yes	37/45	3.4 (2.2-4.8)	37/50	3.7 (1.9-7.2)	_ ⊢_ ∎			0.96 (0.61-1.52)
No	37/66	9.6 (7.5-11.2)	36/65	9.3 (7.4-14.7)	⊢ ∎			0.95 (0.60-1.51)
No. of previous VEGFR-TKIs (any	prior line)							
0	29/53	9.6 (7.4-15.3)	28/53	9.4 (7.4-15.5)	· ·	—		1.03 (0.61-1.74)
1	69/96	5.4 (3.7-6.7)	70/101	7.4 (5.5-8.8)	⊢	4		1.04 (0.74-1.45)
2	20/22	3.1 (2.1-4.0)	14/18	3.8 (1.9-7.2)	· ⊢ -			1.33 (0.67-2.65)
			🔶 Tivo	ozanib + Nivolumab∣	better Ti	vozanib be	etter —	
ONA CONGRESS				Г [—]		2	3	

BAR0 2024

ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; ICI, immune checkpoint inhibitor; IMDC, International mRCC Database Consortium; IRR, independent radiology review; PFS, progression-free survival; VEGFR-TKI, vascular endothelial growth factor receptor tyrosine kinase inhibitor.

Overall Survival





Best Overall Response per Central Review

	Tivozanib + Nivolumab (n=171)	Tivozanib (n=172)
ORR, n (%) [95% Cl]	33 (19.3) [13.7-26.0]	34 (19.8) [14.1-26.5]
CR, n (%)	1 (0.6)	1 (0.6)
PR, n (%)	32 (18.7)	33 (19.2)
SD, n (%)	74 (43.3)	81 (47.1)
PD, n (%)	49 (28.7)	43 (25.0)
NE, n (%)	15 (8.8)	14 (8.1)
mDOR (95% CI), mo	15.77 (5.65-NR)	9.66 (3.71-NR)

Included are patients who presented with measurable disease according to RECIST 1.1, as assessed by central review.

CR, complete response; mDOR, median duration of response; NE, not evaluable; NR, not reached. ORR, objective response rate; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.



Safety Summary

Adverse event	Tivozanib 0.89 mg + Nivolumab (n=168)	Tivozanib 1.34 mg (n=171)
Any-cause TEAE, n (%)	163 (97)	167 (98)
Related TEAE	137 (82)	144 (84)
Tivozanib	135 (80)	144 (84)
Nivolumab	119 (71)	0
Grade ≥3 AE, n (%)	102 (61)	103 (60)
Related	54 (32)	60 (35)
Serious AE, n (%)	54 (32)	64 (37)
Related	14 (8)	15 (9)
Death due to AE, n (%)	7 (4)	5 (3)
Related	0	1 (<1)
TEAE leading to discontinuation, n (%)	27 (16)	33 (19)
Due to tivozanib	19 (11)	33 (19)
Due to nivolumab	22 (13)	0
TEAE leading to dose interruption, n (%)	82 (49)	93 (54)
Due to tivozanib	79 (47)	93 (54)
Due to nivolumab	35 (21)	0
TEAE leading to dose reduction of tivozanib, n (%)	18 (11)	38 (22)
Median duration of treatment (range), months	6.3 (0.0-20.7)	7.4 (0.1-17.9)



Most Common All-Grade Adverse Events Regardless of Causality

Adverse event, n (%) ^a	Tivozanib 0.89 mg + Nivolumab (n=168)	Tivozanib 1.34 mg (n=171)
Hypertension	62 (37)	69 (40)
Fatigue	49 (29)	68 (40)
Diarrhea	51 (30)	62 (36)
Nausea	26 (16)	47 (28)
Decreased appetite	37 (22)	46 (27)
Vomiting	20 (12)	36 (21)
Asthenia	39 (23)	35 (21)
Proteinuria	16 (10)	30 (18)
Constipation	17 (10)	29 (17)
Arthralgia	26 (16)	27 (16)
Cough	26 (16)	26 (15)
Hypothyroidism	15 (9)	26 (15)
Anemia	28 (17)	16 (9)
Pruritus	26 (16)	11 (6)

^a Treatment-emergent adverse events occurring in ≥15% of patients in either arm.



Conclusions

- TiNivo-2 was the first randomized, phase 3 trial to evaluate the efficacy and safety of a **PD-1 inhibitor** combination following progression on or after prior treatment with PD-1/PD-L1 therapy
- The addition of nivolumab to tivozanib did not result in improved clinical outcomes in patients with mRCC whose disease progressed on or after prior ICI treatment
 - No subgroup was identified that benefited from the addition of nivolumab
- This trial confirms and expands key conclusions from CONTACT-03, and suggests that ICI rechallenge should be generally discouraged regardless of treatment sequence
- The reduced dose of tivozanib in the combination arm may have impacted the efficacy reflected by the numerically lower mPFS
- Meaningful efficacy was observed in the second-line tivozanib monotherapy arm, with a 9.2month mPFS immediately following ICI
- These results support tivozanib monotherapy at 1.34 mg as a second-line therapy option in patients following progression on previous ICI therapy



Acknowledgements

We express our gratitude to the patients and their caregivers for their invaluable contributions. We also extend our thanks to the clinical study teams, investigators, and steering committee.

This study is sponsored by AVEO Pharmaceuticals, Inc. Nivolumab was provided by Bristol Myers Squibb.

Medical writing assistance for this oral presentation was provided by Bonisile Luthuli of Nucleus Global and funded by AVEO Pharmaceuticals, Inc.



Thank You to the Investigators

Argentina

Ernesto Korbenfeld Felipe Palazzo Luis Enrique Fein Marcos Flores Ruben Dario Kowalyszyn Australia Anthony Dowling David Campbell Elizabeth McCaffrev Mark Frydenberg Niara Oliveira Sina Vatandoust Wei Chua

Belaium

Alain Bots Daisy Luyten Philip Debruyne Sideris Spyridon Sylvie Lecomte Svlvie Rottev Van Wambeke Simon Wesley Teurfs Brazil Andre Fay Felipe Cruz **Giuliano Santos Borges** Gustavo Alves Ubiraiara Ferreira

Alan Azambuia

Canada Daniel Heng Georg Bjarnason Srikala Sridhar Christian Kollmannsberger

Chile

Ariel Zwenger Kloster Eugenia Loredo Fort Mauricio Burotto Pichun Mauricio Reves Cartes Alejandro Acevedo Gaete


Czech Republic

Eugen Kubala Jan Dvorak Jindrich Kopecky Martin Smakal Zdenek Kral



Giuseppa Scandurra Linda Cerbone Lorenzo Livi Marilena Di Napoli Michele DE Tursi Pierfrancesco Tassone Roberto lacovelli Sergio Bracarda Silvia Chiellino Ugo De Giorgi

ngress



Andre Mansinho Andre Oliveira Catarina Santos Catia Faustino Joana Febra

Cristina Suarez Rodriguez Guillermo de Velasco Oria de Rueda Enrique Gallardo Federico Jose Vazquez Mazon Francisco Xavier Garcia del Muro Solans Georgia Anguera Palacios Javier Molina-Cerrillo

Javier Puente Vazquez Maria del Carmen Garcias de Espana Miguel Climent Duran Nuria Sala Olatz Etxaniz Ulazia Ovidio Fernandez Calvo Regina Girones Sarrio Virizuela Echaburu Juan

United Kingdom Manon Pillai Mohammad Sarwar Brent O'Carrigan Naveen Vasudev Carey Macdonald-Smith Omi Parikh Prantik Das Sing Moorcraft United States Nataliva Mar Neda Hashemi Nicholas Vogelzang Nicklas Pfanzelter Benjamin Garmezy Patrick Cobb Bradley McGregor Pedro Barata Philip Lammers Christian Thomas Raiat Malhotra Ralph Hauke Rana McKay **Richard Zuniga** Robert Motzer Edward Arrowsmith Robert Muldoon Robert Weaver Elizabeth Guancial Saby George Sandy Srinivas Elizabeth Wulff-Burchfield Shachar Peles Heather Mannuel Shenhong Wu Sherronda Henderson Shifeng Mao Sridhar Beeram Sumanta Pal Kanaan Mohammed Suresh Nair Kathrvn Beckermann Teiwani Sheela Matthew Zibelman Thomas Hutson Megan Wheelden Tvkodi Scott Yasser Ged Yue Zhang Zin Myint

Anand Sharma

Ekaterini Boleti

Anthony Pham

Kate Young

Allen Cohn

Arnab Basu

Aung Bajaj

Brian Lewis

Daniel Bowles

David Park

Eun-mi Yu

Helen Moon

Jeffrey Yorio

Mike Cusnir

Milan Sheth

Moshe Ornstein

Jun Sun

Isaac Bowman

Dhruy Bansal

Elisabeth Heath

Coty Ho

Ankit Jain

16

THE LANCET

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

Toni K Choueiri, Laurence Albiges*, Philippe Barthélémy, Roberto Iacovelli, Sheik Emambux, Javier Molina-Cerrillo, Benjamin Garmezy, Pedro Barata, Arnab Basu, Maria T Bourlon, Helen Moon, Raffaele Ratta, Rana R McKay, Alexander Chehrazi-Raffle, Hans Hammers, Daniel Y C Heng, Edgar Braendle, Kathryn E Beckermann, Bradley A McGregor, Robert J Motzer*

